Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EPS (Weighted Average and Diluted) (2022 - 2025)

Historic EPS (Weighted Average and Diluted) for Dianthus Therapeutics (DNTH) over the last 4 years, with Q3 2025 value amounting to -$0.97.

  • Dianthus Therapeutics' EPS (Weighted Average and Diluted) fell 3108.11% to -$0.97 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.49, marking a year-over-year decrease of 14874.3%. This contributed to the annual value of -$2.54 for FY2024, which is 6998.28% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported EPS (Weighted Average and Diluted) of -$0.97 as of Q3 2025, which was down 3108.11% from -$0.88 recorded in Q2 2025.
  • Dianthus Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $8.95 for Q4 2023, and its period low was -$12.73 during Q2 2023.
  • In the last 4 years, Dianthus Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.88 in 2025 and averaged -$3.19.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first soared by 17735.52% in 2023, then tumbled by 10936.61% in 2024.
  • Dianthus Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$11.57 in 2022, then surged by 177.36% to $8.95 in 2023, then plummeted by 109.37% to -$0.84 in 2024, then decreased by 15.71% to -$0.97 in 2025.
  • Its last three reported values are -$0.97 in Q3 2025, -$0.88 for Q2 2025, and -$0.82 during Q1 2025.